SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 4366.
  • 2
    Motzer RJ,Bacik J,Murphy BA,Russo P,Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289296.
  • 3
    Escudier B,Eisen T,Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125134.
  • 4
    Hudes G,Carducci M,Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 22712281.
  • 5
    McDermott DF,Regan MM,Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133141.
  • 6
    Motzer RJ,Hutson TE,Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115124.
  • 7
    Pyrhonen S,Salminen E,Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999; 17: 28592867.
  • 8
    Kanyshkova TG,Buneva VN,Nevinsky GA. Lactoferrin and its biological functions. Biochemistry (Mosc). 2001; 66: 17.
  • 9
    Gahr M,Speer CP,Damerau B,Sawatzki G. Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes. J Leukoc Biol. 1991; 49: 427433.
  • 10
    Bellamy W,Takase M,Wakabayashi H,Kawase K,Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol. 1992; 73: 472479.
  • 11
    Vorland LH. Lactoferrin: a multifunctional glycoprotein. APMIS. 1999; 107: 971981.
  • 12
    Wright DG,Gallin JI. Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol. 1979; 123: 285294.
  • 13
    Varadhachary A,Wolf JS,Petrak K, et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer. 2004; 111: 398403.
  • 14
    Spadaro M,Curcio C,Varadhachary A, et al. Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. Cancer Res. 2007; 67: 64256432.
  • 15
    Ward PP,Piddington CS,Cunningham GA,Zhou X,Wyatt RD,Conneely OM. A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology (N Y). 1995; 13: 498503.
  • 16
    Hayes TG,Falchook GF,Varadhachary GR, et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs. 2006; 24: 233240.
  • 17
    Varadhachary A,Spadaro M,Engelmayer J, et al. Talactoferrin alfa is an anti-cancer agent with activity in renal cell cancer (RCC) patients and a novel immunomodulatory mechanism of action. Proc Am Soc Clin Oncol. 1996; Vol: 14648.
  • 18
    Wang Y,Raghunadharao D,Raman G, et al. Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial. Proc Am Soc Clin Oncol. 2006;VOL: 7095.
  • 19
    Parikh PM,Wang Y,Ranade AA, et al. Oral talactoferrin extends survival in patients with recurrent NSCLC in a randomized placebo-controlled phase 2 trial. Proc Am Soc Clin Oncol. 2007;VOL: 7540.
  • 20
    Yang JC,Haworth L,Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427434.
  • 21
    Jocham D,Richter A,Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004; 363: 594599.
  • 22
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 23
    Prasad SR,Saini S,Sumner JE,Hahn PF,Sahani D,Boland GW. Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr. 2003; 27: 380384.
  • 24
    Therasse P,Le Cesne A,Van Glabbeke M,Verweij J,Judson I. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer. 2005; 41: 14261430.
  • 25
    Osada T,Chong G,Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008 Jan 10 [Epub ahead of print].